Key Details
Price
$0.51Annual ROE
-59.95%Beta
1.15Events Calendar
Next earnings date:
Mar 14, 2025Recent quarterly earnings:
Dec 10, 2024Recent annual earnings:
July 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 23, 2020Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) today announced that Kristin Taylor has resigned from her position as Chief Financial Officer effective January 16, 2025. Ms. Taylor will continue to serve in the role of CFO until January 16, 2025, and will remain available to the company on a consulting basis after that time. “Kristin has been a valued member of our team over this past year," said Dr. Jennifer Bath, IPA's President and Chief Executive Officer. ".
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce significant insider activity, with key members of its executive team and subsidiary co-founders demonstrating confidence in the Company's strategic direction and long-term potential through substantial share purchases. Over the past week, CEO Dr. Jennifer Bath and BioStrand co-founders Dirk Va.
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q2 2025 Earnings Conference Call December 10, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants Swayampakula Ramakanth - H.C.
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.05.
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, announces the details of its upcoming TECHDAY event on Friday, November 15, 2024, from 9:00 a.m. to 12:30 p.m. EST in Cambridge, Massachusetts. This exclusive gathering will highlight IPA's latest advancements in AI-driven design, biologics innovation, and strategic technological developments. Highlights of TECHDAY: Prese.
LOS ANGELES--(BUSINESS WIRE)-- #apartmentbrokers--Institutional Property Advisors Brokers $92.5 Million Multifamily Sale in L.A.'s NoHo Arts District.
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA ) Q1 2025 Earnings Conference Call September 16, 2024 10:30 AM ET Company Participants Jennifer Bath - CEO Kristin Taylor - CFO Conference Call Participants Swayampakula Ramakanth - H.C.
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.09.
VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2025, on Monday, September 16, 2024, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecis.
ImmunoPrecise Antibodies Ltd. (IPA) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.10.
FAQ
- What is the primary business of ImmunoPrecise Antibodies?
- What is the ticker symbol for ImmunoPrecise Antibodies?
- Does ImmunoPrecise Antibodies pay dividends?
- What sector is ImmunoPrecise Antibodies in?
- What industry is ImmunoPrecise Antibodies in?
- What country is ImmunoPrecise Antibodies based in?
- When did ImmunoPrecise Antibodies go public?
- Is ImmunoPrecise Antibodies in the S&P 500?
- Is ImmunoPrecise Antibodies in the NASDAQ 100?
- Is ImmunoPrecise Antibodies in the Dow Jones?
- When was ImmunoPrecise Antibodies's last earnings report?
- When does ImmunoPrecise Antibodies report earnings?